Pure Global
NCT05979896

Chemoprevention Efficacy Study Nigeria

A Study Protocol to Assess the Chemoprevention Efficacy of Sulphadoxine-Pyrimethamine Plus Amodiaquine (SPAQ) and Resistance Marker Prevalence in Children 3-59 Months in Sokoto and Kwara States, Nigeria.
Malaria Consortium·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Standard age based SPAQ administration for SMC
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Malaria Consortium
Location
Kwara, Nigeria
Timeline & enrollment
Phase
Phase 4
Start date
Jul 28, 2023
End date
May 15, 2024
Enrollment
800 participants
Primary outcome

Chemoprevention failure as defined by qPCR positive parasites or malaria slide positive parasites,Prevalence of antimalarial resistance markers among chemoprevention failures (as defined in outcome 1),Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1),Prevalence over time of parasites with dhfr/dhps/pfcrt/pfmdr1 mutations in symptomatic children with a positive diagnostic test residing in districts where SMC is implemented

Summary

The study aims to assess the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and
 Amodiaquine (SPAQ) used in standard age-based dosing regimens used in Seasonal Malaria
 Chemoprevention (SMC) and SPAQ resistance marker prevalences and assocations among children 3
 - 59 months in Sokoto and Kwara States, Nigeria.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05979896
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05979896 through Pure Global AI's free database. This Phase 4 trial is sponsored by Malaria Consortium and is currently Recruiting. The study focuses on Malaria. Target enrollment is 800 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.